BOSTON SCIENTIFIC CORP
NYSE: BSX·Marlborough, Massachusetts·CIK 0000885725
- Price
- $43.69
- Base IV
- $39.97
Valuation snapshot
At $43.69, the price sits between our base case ($39.97) and bull case ($67.35).
Values per share, from an .
- No growth
- …
- Loading earnings power
- Base case
- $39.97
- 91% of the price · range $20.69–$67.35
- Price vs base case
- 9% above
- $43.69 against $39.97
- Base case · our researched forecast, 2026-11-05See the research ↗
- Price vs base · derived: price − base caseWhat the price expects ↗
- Price · StockValuer price feed, 2026-11-16 closeno link today
The price has fallen 4.6% since this valuation was struck on 2026-11-05, so some of the gap opened up after these figures were set.
Whisker on the base case runs bear $20.69 to bull $67.35. Values per share.
Price against each value
- Bear case
- $20.69
- Price 111% above
- No growth
- …
- —
- Base case
- $39.97
- Price 9% above
What does Boston Scientific do?
Boston Scientific develops and manufactures medical devices for physicians to diagnose and treat cardiovascular, respiratory, digestive, and urological conditions through minimally invasive procedures.
It brought in $21.1B of sales in the 12 months to Sep 2026.
Led by Michael F. Mahoney, Chairman of the Board, President and Chief Executive Officer since 2012. Notice of 2024 Annual Meeting of Stockholders and Proxy Statement
- Industry
- Healthcare
- Based in
- Marlborough, Massachusetts
- Trades on
- NYSE as BSX
Here is where each dollar a customer pays ends up. Out of every $1 of sales in the 12 months to Sep 2026, about 17¢ was left as profit after every cost, interest and tax. The biggest cost is sales, marketing and admin, 34¢ of every dollar.
- Making what it sells31¢
- Research and development10¢
- Sales, marketing and admin34¢
- Everything else it takes to operate7¢
- Interest and other costs1¢
- Tax1¢
- Left as profit17¢
Who pays Boston Scientific, and for what?
Boston Scientific makes medical devices used to diagnose and treat conditions affecting the heart, blood vessels, digestive and urinary systems, and nervous system. It earns revenue by selling these devices and related technologies to health care providers around the world.
Its products are bought mainly by hospitals, clinics, outpatient facilities, medical offices and other health care providers; group purchasing organizations and hospital networks also account for a substantial portion of sales.
Cardiovascular
66%Devices and technologies for heart, blood vessel and cancer treatments, including electrophysiology, WATCHMAN, cardiac rhythm management and vascular therapies.
Endoscopy
15%Minimally invasive devices for diagnosing and treating digestive and pancreaticobiliary conditions, and supporting weight loss.
AXIOS stent and delivery systemImage: Boston Scientific Urology
13%Devices for kidney stones, prostate conditions, erectile dysfunction, incontinence and pelvic floor disorders.
LithoVue Elite single-use digital flexible ureteroscope systemImage: Boston Scientific Neuromodulation
6%Devices to manage chronic pain and treat neurological movement disorders.
Where its work physically happens, beyond headquarters:
- Galway campus — Galway, Ireland. The site combines medical device manufacturing with cardiovascular R&D, and Boston Scientific announced a €75 million investment to expand its development capacity.
- Maple Grove facility — Maple Grove, United States. Boston Scientific identifies Maple Grove as both a principal manufacturing facility and an R&D center, making it important to device production and development.
- Clonmel facility — Clonmel, Ireland. Clonmel is one of Boston Scientific’s principal Irish manufacturing facilities and also houses an R&D center.
- Coyol facility — Alajuela, Costa Rica. The 2025 Form 10-K identifies Coyol as a principal owned manufacturing facility within Boston Scientific’s Costa Rican production network.
- Arden Hills facility — Arden Hills, United States. Boston Scientific lists Arden Hills as both a principal manufacturing facility and an R&D center, tying the site to production and product development.
How is the business doing?
Sales grew from $9.9B in 2020 to $20.1B in 2025, about 15% a year.
Running the business leaves about 19¢ of each sales dollar as operating profit, up from 1¢ in 2020.
After paying for its upkeep and new investment, it had $3.3B of cash to spare in the 12 months to Sep 2026.
What does management say it's aiming for?
The company says it exists to improve patients’ health around the world with innovative medical solutions.
“transform lives through innovative medical solutions that improve the health of patients around the world”
Who is responsible for the plan?
- Michael F. MahoneyChairman of the Board, President and Chief Executive Officer
He oversees global business strategy, corporate operations, and the worldwide development and commercialization of Boston Scientific's medical solutions portfolio. Boston Scientific generates revenue by developing, manufacturing, and marketing medical devices across cardiovascular and medical surgical markets.
- Joseph M. FitzgeraldExecutive Vice President and Group President, Cardiovascular
He oversees the global development, commercialization, and operational strategy of the Cardiovascular segment and Peripheral Interventions business. The Cardiovascular segment generates revenue through the sale of advanced medical devices and solutions for interventional cardiology, rhythm management, and electrophysiology procedures.
- Jodi EddySenior Vice President, Enterprise Services and Digital Officer
She oversees the global information technology organization, expanded digital teams, cybersecurity, artificial intelligence, data analytics, and digital health strategies. Enterprise digital systems, data analytics, cybersecurity, and digital health infrastructure support connected medical devices and essential product and business capabilities.
Roles checked November 14, 2026.
What management says it is working on now:
Address WATCHMAN market headwinds
Management plans more physician education and evidence sharing, stronger engagement with hospitals, and direct outreach to help appropriate patients learn about the treatment.
Boston Scientific Q2 2026 Earnings Call TranscriptImprove U.S. electrophysiology performance
Management is focused on expanding access to its pulsed field ablation products and developing its product lineup, while responding to competitive share shifts.
Boston Scientific Q2 2026 Earnings Call TranscriptStrengthen urology and cardiac rhythm management
Management expects business improvements as it addresses gaps in urology and prepares new cardiac rhythm management products.
Boston Scientific Q2 2026 Earnings Call TranscriptControl costs and reinvest for growth
A restructuring program is intended to lower ongoing costs while directing resources toward areas management sees as having strong long-term opportunities.
Boston Scientific Q2 2026 Earnings Call TranscriptExpand through innovation and global markets
The company plans to invest in research, improve existing products, develop new technologies and grow in international and emerging markets.
Boston Scientific 2025 Form 10-K
- Adjusted operating margin expansion, 2026
- 0 to 25 basis points
- Boston Scientific Q2 2026 Earnings Call Transcript
- Annual run-rate savings from restructuring, Exiting 2029
- Approximately $500 million
- Boston Scientific Q2 2026 Earnings Call Transcript
What's changing right now?
Growth is slowing. In Q3 2026 it sold 1% more than a year earlier. The year before, quarters averaged 14%.
Its operating margin is narrower than a year ago: 16¢ per sales dollar, against 21¢.
Since Oct 2026 the share price has risen 2%, from $42.69 to $43.69.
Recently
February 19, 2026
Cardiovascular Net Sales, Full Year changed to $13.3B
Boston Scientific Form 10-K FY2025December 31, 2025
Annual property and software spending per sales changed to 4.4%
2025 Form 10-K cash flowsDecember 31, 2025
Annual tax rate from continuing operations changed to 18.9%
2025 Form 10-K tax table
Coming up
Expected during 2026
Penumbra acquisition
Boston Scientific has agreed to acquire Penumbra for approximately $14.5 billion. The deal is subject to customary closing conditions and is expected to close during 2026.
Boston Scientific 2025 Form 10-KSecond half of 2027
FARAWAVE Ultra and ICE market entry
Management expects U.S. electrophysiology performance to improve after introducing FARAWAVE Ultra and entering the intracardiac echocardiography market.
Boston Scientific Q2 2026 Earnings Call TranscriptFirst half of 2027
SEISMIQ 4CE coronary catheter
Management said it expects to bring this coronary intravascular lithotripsy catheter to market.
Boston Scientific Q2 2026 Earnings Call TranscriptOctober 28, 2026
Third-quarter 2026 results call
The company has scheduled a conference call to discuss its third-quarter financial results.
Events & Presentations – Boston Scientific
Our own estimate moved too: the base case went from $25.07 to $39.97 a share between our last two valuations.
What could go wrong?
No business is a sure thing. These are the risks we found, starting with the ones the company itself names. Where a risk would change part of the valuation, it says which.
Competition and fast-changing technology
Rivals, lower-priced products and alternative treatments may take customers or make the company’s products less competitive. Delayed or unsuccessful product development could also hurt sales.
From the company's own filingsWould hit how fast sales growBoston Scientific 2025 Form 10-K
Pricing, procedure and reimbursement pressure
Hospitals and other buyers are consolidating, while governments and insurers seek to contain health care costs. Lower prices, reduced coverage or fewer procedures using its devices could weaken sales.
From the company's own filingsWould hit how fast sales growBoston Scientific 2025 Form 10-K
Regulatory approval and compliance
Medical devices need approvals in the markets where they are sold, and requirements can change. Delays, recalls or other regulatory actions could restrict sales or raise costs.
From the company's own filingsWould hit how fast sales growBoston Scientific 2025 Form 10-K
Product development and launch execution
New products require research, clinical studies and regulatory approval, and may not gain acceptance. Delays or weak results could limit growth, especially for products management expects to contribute meaningfully.
From the company's own filingsWould hit how fast sales growBoston Scientific 2025 Form 10-K
Supply interruptions and rising costs
Some components come from single suppliers, and manufacturing or sterilization disruptions could limit product availability. Material shortages, tariffs and higher costs could also pressure results.
From the company's own filingsWould hit how much of each sale it keepsBoston Scientific 2025 Form 10-K
Acquisition and debt exposure
Acquisitions take time and resources to integrate and may not deliver expected benefits. The company also says higher debt or weaker cash flow could raise borrowing costs and limit financial flexibility.
From the company's own filingsWould hit how much of each sale it keepsBoston Scientific 2025 Form 10-K
Management provided a Q4 2026 sales guidance projection ranging between a 3% decline and a 1% decline YoY.
From our researchWould hit how fast sales growBoston Scientific Q3 2026 Earnings Release
Operational and computer network remediation costs in late 2026 drove quarterly operating margin down to 16.12%.
From our researchWould hit how much of each sale it keepsBoston Scientific Form 10-Q Q3 2026
Is it a good business?
From 2016 to 2025 it earned between -0% and 9% on the capital invested in it, a median of 6%. Its cost of capital in the latest valuation is 7.4%; returns were above it in 3 of the 10 years.
From 2016 to 2025 it earned between -1% and 34% on its shareholders' equity, a median of 7%.
Over 10 years its operating margin ranged from 1¢ to 18¢ per sales dollar, a median of 14¢. Gross margin ran from 65¢ to 71¢.
Cost of capital 7.4%
It bought back shares: the count fell 2.9% in a year, so each remaining share owns a slightly bigger slice.
It owes $11.3B more than it holds in cash, about 2.9 years of operating profit.
What might it be worth?
The Valuation snapshot at the top of this page shows the answer. This is how we got there. A share is a slice of the business, so what a share is worth depends on what the business can earn for its owners from here on. We estimate that three ways, from cautious to hopeful, and call the result .
Today a share costs $43.69. Our put its value between $20.69 and $67.35, with $39.97 in the middle. Underneath sit two simpler checks: what it would cost to rebuild the business, its , and what today's profit is worth with no growth at all, its .
Bear case, $20.69
This scenario envisions Boston Scientific's expansion cooling significantly from its recent twenty percent annual pace down to low single digits as competition intensifies in heart devices and temporary operational disruptions linger.
Base case, $39.97
This scenario projects that Boston Scientific rebounds from recent operational bottlenecks to deliver mid-single-digit sales growth and steady profit efficiency, supported by ongoing worldwide demand for its flagship cardiac and surgical technologies.
Bull case, $67.35
This scenario models a powerful growth reacceleration back toward double digits as international market expansion for next-generation ablation tools and stroke-prevention implants drives market share gains and expanding profitability.
Another way in: instead of asking what the business is worth, ask what today's price assumes it will do.
Why the gap?
The price expects more than we do.Price above value: 9%
For Boston Scientific to be worth today's $43.69, sales would need to grow about 8.1% a year. We assume 6.3%. Over the last 5 years, sales grew 12.9% a year.
Or, if sales grow 6.3% as we assume, the price works with a profit margin of 21.6% (we assume 20.0%).
Keep in mind: this is one way to read the price. Investors might be expecting other things, like higher profits or lower risk.
Do you think sales can grow 8.1% a year?
Try your own numbersWe're moderately sure of this range: it scores 64 out of 100 on our checks. The weakest point is terminal-value dependency.
Test the assumptions
Our base value of $39.97 rests on three assumptions. Change any of them to see how the value per share responds.
- Revenue growth, 5-year average6.3%
- Operating margin20.0%
- Long-term growth rate2.8%
This is an educational explanation built from public filings and our own research, not investment advice. It does not tell you whether to buy or sell anything.
Base estimate
$39.97 -8.5%


